 Kendra Conzen
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 19 | 2024 | 841 | 2.280 |
Why?
| | Kidney Transplantation | 8 | 2026 | 732 | 1.040 |
Why?
| | Tissue Donors | 5 | 2026 | 427 | 0.880 |
Why?
| | Robotic Surgical Procedures | 4 | 2026 | 207 | 0.770 |
Why?
| | Living Donors | 9 | 2023 | 289 | 0.680 |
Why?
| | Obesity, Morbid | 4 | 2020 | 298 | 0.650 |
Why?
| | Venous Thrombosis | 2 | 2021 | 199 | 0.580 |
Why?
| | Liver Cirrhosis | 2 | 2020 | 289 | 0.580 |
Why?
| | Postoperative Complications | 5 | 2026 | 3022 | 0.560 |
Why?
| | Portal Vein | 2 | 2021 | 124 | 0.510 |
Why?
| | Transplant Recipients | 3 | 2023 | 183 | 0.440 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 95 | 0.420 |
Why?
| | Gastric Bypass | 3 | 2020 | 126 | 0.400 |
Why?
| | Graft Survival | 8 | 2026 | 534 | 0.390 |
Why?
| | Cholestasis | 2 | 2016 | 217 | 0.380 |
Why?
| | Tissue and Organ Procurement | 4 | 2026 | 350 | 0.370 |
Why?
| | Body Mass Index | 4 | 2026 | 2470 | 0.330 |
Why?
| | Catheterization | 1 | 2011 | 184 | 0.330 |
Why?
| | Decompression, Surgical | 1 | 2011 | 117 | 0.320 |
Why?
| | Drainage | 1 | 2011 | 189 | 0.320 |
Why?
| | Donor Selection | 3 | 2025 | 79 | 0.310 |
Why?
| | Tissue Plasminogen Activator | 2 | 2023 | 248 | 0.310 |
Why?
| | Reperfusion Injury | 4 | 2014 | 294 | 0.300 |
Why?
| | Liver | 9 | 2023 | 1916 | 0.280 |
Why?
| | Nephrectomy | 2 | 2026 | 172 | 0.260 |
Why?
| | Brain Death | 1 | 2026 | 60 | 0.230 |
Why?
| | Treatment Outcome | 10 | 2026 | 11947 | 0.230 |
Why?
| | Polycystic Kidney Diseases | 1 | 2026 | 82 | 0.230 |
Why?
| | Graft Rejection | 2 | 2020 | 523 | 0.200 |
Why?
| | Kidney Failure, Chronic | 2 | 2020 | 600 | 0.200 |
Why?
| | Perioperative Care | 2 | 2017 | 231 | 0.200 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2026 | 244 | 0.190 |
Why?
| | Thrombelastography | 2 | 2020 | 192 | 0.180 |
Why?
| | Retrospective Studies | 12 | 2026 | 17560 | 0.180 |
Why?
| | Fatty Liver | 3 | 2014 | 257 | 0.180 |
Why?
| | Informed Consent | 1 | 2024 | 200 | 0.180 |
Why?
| | Organ Transplantation | 1 | 2025 | 258 | 0.170 |
Why?
| | Reperfusion | 1 | 2020 | 54 | 0.160 |
Why?
| | Waiting Lists | 2 | 2025 | 268 | 0.160 |
Why?
| | Humans | 32 | 2026 | 147293 | 0.150 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 52 | 0.150 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 104 | 0.150 |
Why?
| | Adult | 15 | 2026 | 41405 | 0.150 |
Why?
| | Male | 18 | 2026 | 73950 | 0.140 |
Why?
| | Middle Aged | 13 | 2026 | 36821 | 0.140 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 2133 | 0.140 |
Why?
| | Blood Coagulation | 1 | 2020 | 274 | 0.140 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 198 | 0.140 |
Why?
| | Telomerase | 1 | 2020 | 250 | 0.130 |
Why?
| | Transplantation, Homologous | 3 | 2020 | 422 | 0.130 |
Why?
| | Phlebography | 1 | 2017 | 41 | 0.130 |
Why?
| | Resuscitation | 1 | 2020 | 318 | 0.130 |
Why?
| | Obesity | 3 | 2026 | 3149 | 0.130 |
Why?
| | Incidental Findings | 1 | 2017 | 82 | 0.130 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 104 | 0.120 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 126 | 0.120 |
Why?
| | Allografts | 1 | 2017 | 152 | 0.120 |
Why?
| | Female | 15 | 2026 | 80076 | 0.120 |
Why?
| | Bariatric Surgery | 1 | 2020 | 258 | 0.120 |
Why?
| | Sex Factors | 2 | 2024 | 2136 | 0.120 |
Why?
| | Delayed Graft Function | 2 | 2026 | 54 | 0.120 |
Why?
| | Anticoagulants | 2 | 2021 | 751 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 136 | 0.110 |
Why?
| | Surgeons | 1 | 2020 | 342 | 0.110 |
Why?
| | Operative Time | 2 | 2026 | 195 | 0.110 |
Why?
| | Airway Extubation | 1 | 2016 | 60 | 0.110 |
Why?
| | General Surgery | 1 | 2018 | 207 | 0.110 |
Why?
| | BH3 Interacting Domain Death Agonist Protein | 1 | 2014 | 11 | 0.110 |
Why?
| | Missouri | 2 | 2011 | 67 | 0.110 |
Why?
| | Vascular Surgical Procedures | 1 | 2018 | 347 | 0.110 |
Why?
| | Parents | 2 | 2020 | 1428 | 0.100 |
Why?
| | Hospitals, University | 1 | 2014 | 176 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 2 | 2017 | 2791 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 187 | 0.100 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 190 | 0.100 |
Why?
| | Gastrectomy | 3 | 2020 | 169 | 0.100 |
Why?
| | Burnout, Professional | 1 | 2020 | 490 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 568 | 0.090 |
Why?
| | Reoperation | 2 | 2016 | 644 | 0.090 |
Why?
| | Time Factors | 4 | 2020 | 7173 | 0.090 |
Why?
| | Cholangiography | 1 | 2011 | 10 | 0.090 |
Why?
| | Warm Ischemia | 2 | 2026 | 28 | 0.080 |
Why?
| | Radiographic Image Enhancement | 1 | 2011 | 57 | 0.080 |
Why?
| | Survival Analysis | 1 | 2014 | 1386 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 627 | 0.080 |
Why?
| | Registries | 1 | 2020 | 2434 | 0.080 |
Why?
| | Molecular Chaperones | 1 | 2012 | 199 | 0.080 |
Why?
| | Fibrinolysis | 2 | 2023 | 164 | 0.080 |
Why?
| | Prevalence | 1 | 2017 | 2889 | 0.080 |
Why?
| | Clinical Competence | 1 | 2018 | 1260 | 0.070 |
Why?
| | United States | 4 | 2024 | 16313 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5476 | 0.070 |
Why?
| | Neoplasms | 1 | 2025 | 2946 | 0.070 |
Why?
| | Liver Diseases | 1 | 2012 | 307 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 4130 | 0.070 |
Why?
| | Endoplasmic Reticulum | 1 | 2011 | 269 | 0.070 |
Why?
| | Hypoxia | 1 | 2016 | 1208 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 8164 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2014 | 1171 | 0.070 |
Why?
| | Stress, Physiological | 1 | 2011 | 445 | 0.070 |
Why?
| | Imaging, Three-Dimensional | 1 | 2011 | 587 | 0.060 |
Why?
| | Stents | 1 | 2011 | 570 | 0.060 |
Why?
| | Aged | 5 | 2026 | 26514 | 0.060 |
Why?
| | Heart Failure | 1 | 2020 | 2334 | 0.060 |
Why?
| | Hepatectomy | 2 | 2023 | 280 | 0.060 |
Why?
| | Proteomics | 1 | 2012 | 1203 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3784 | 0.050 |
Why?
| | Prognosis | 2 | 2024 | 4383 | 0.050 |
Why?
| | Hepatitis C Antibodies | 1 | 2004 | 11 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2012 | 4604 | 0.050 |
Why?
| | Immunodominant Epitopes | 1 | 2004 | 27 | 0.050 |
Why?
| | Cohort Studies | 1 | 2014 | 6099 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 10 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 26 | 0.050 |
Why?
| | Antibody Formation | 1 | 2004 | 288 | 0.050 |
Why?
| | Bile Ducts | 1 | 2022 | 68 | 0.050 |
Why?
| | Hepacivirus | 1 | 2004 | 243 | 0.050 |
Why?
| | Rats, Zucker | 2 | 2012 | 32 | 0.040 |
Why?
| | Creatinine | 1 | 2023 | 516 | 0.040 |
Why?
| | Dabigatran | 1 | 2021 | 30 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 69 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 55 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 92 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 105 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2020 | 156 | 0.040 |
Why?
| | Child | 3 | 2021 | 22979 | 0.040 |
Why?
| | Length of Stay | 1 | 2026 | 1371 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.040 |
Why?
| | Kidney | 1 | 2026 | 1511 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3980 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 167 | 0.030 |
Why?
| | Critical Care | 1 | 2023 | 705 | 0.030 |
Why?
| | Infant | 1 | 2011 | 10194 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 357 | 0.030 |
Why?
| | Child, Preschool | 1 | 2011 | 12016 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 6164 | 0.030 |
Why?
| | Risk Factors | 2 | 2024 | 11017 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2110 | 0.030 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2014 | 37 | 0.030 |
Why?
| | Shock | 1 | 2016 | 110 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 1005 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 480 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 867 | 0.030 |
Why?
| | Erythrocyte Transfusion | 1 | 2016 | 225 | 0.020 |
Why?
| | Cause of Death | 1 | 2016 | 475 | 0.020 |
Why?
| | Hemoglobins | 1 | 2016 | 386 | 0.020 |
Why?
| | Quality Improvement | 1 | 2022 | 1321 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2954 | 0.020 |
Why?
| | Rats | 2 | 2012 | 5613 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 110 | 0.020 |
Why?
| | Transaminases | 1 | 2012 | 22 | 0.020 |
Why?
| | Databases, Protein | 1 | 2012 | 88 | 0.020 |
Why?
| | Tissue Culture Techniques | 1 | 2012 | 82 | 0.020 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2012 | 121 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 242 | 0.020 |
Why?
| | Taurochenodeoxycholic Acid | 1 | 2011 | 8 | 0.020 |
Why?
| | Activating Transcription Factor 4 | 1 | 2011 | 22 | 0.020 |
Why?
| | Transcription Factor CHOP | 1 | 2011 | 32 | 0.020 |
Why?
| | Organ Size | 1 | 2011 | 465 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2012 | 593 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2011 | 140 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 618 | 0.020 |
Why?
| | Animals | 4 | 2014 | 38410 | 0.020 |
Why?
| | Caspases | 1 | 2011 | 233 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 848 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 728 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 394 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2011 | 507 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2011 | 266 | 0.020 |
Why?
| | Proteome | 1 | 2012 | 520 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 3153 | 0.020 |
Why?
| | Internship and Residency | 1 | 2018 | 1279 | 0.020 |
Why?
| | NF-kappa B | 1 | 2011 | 676 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2011 | 784 | 0.020 |
Why?
| | Software | 1 | 2011 | 683 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4351 | 0.010 |
Why?
| | Viral Core Proteins | 1 | 2004 | 21 | 0.010 |
Why?
| | Cytokines | 1 | 2012 | 2086 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3448 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 849 | 0.010 |
Why?
| | Viral Load | 1 | 2004 | 528 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 6041 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1875 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 14437 | 0.010 |
Why?
| | Peptides | 1 | 2004 | 1003 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 5272 | 0.010 |
Why?
| | Adolescent | 1 | 2016 | 22825 | 0.010 |
Why?
| | Mice | 1 | 2012 | 18491 | 0.010 |
Why?
|
|
Conzen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|